Elion Therapeutics, Inc. — Form D
Elion Therapeutics, Inc. of NEW YORK, NY, a company, filed a Form D exempt-offering notice with the SEC on 2024-06-26. The offering totals $83.8M, of which $25.4M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2024-06-26
- Form: D
- Accession: 0002028346-24-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $83.8M
- Amount sold: $25.4M
- Remaining: $58.4M
- Investors: 6
- Date of first sale: 2024-06-11
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-516941
Issuer
- Name: Elion Therapeutics, Inc.
- CIK: 0002028346
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: C/O DEERFIELD MANAGEMENT COMPANY LP, NEW YORK, NY, 10010
- Phone: 212-551-1600
Officers, directors & promoters (5)
| Name | Role | Location |
|---|
| Jim Flynn | Director | New York, NY |
| Martin Heidecker | Director | Cambridge, MA |
| Jonathan Leff | Director | Ness Ziona, L3 |
| Kieren Marr | Director | Baltimore, MD |
| Kieren Marr | Executive Officer | Baltimore, MD |
More